AGLE Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (27 Nov 2023 @ 16:00):

Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases...

Stats
Today's Volume	43 238.00
Average Volume	59 537.00
Market Cap	48.63M
EPS	$0 ( 2024-03-07 )
Next earnings date	( $0 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.162
ATR14	$2.39 (12.36%)

Insider Trading

Date	Person	Action	Amount	type
2023-12-29	Fairmount Funds Management Llc	Buy	406 038	Common Stock
2023-12-29	Fairmount Funds Management Llc	Sell	3 435 480	Common Stock
2023-12-22	Burrows Scott L	Buy	134 953	Common Stock
2023-12-07	Fairmount Funds Management Llc	Buy	16 667	Series B Preferred Stock
2023-11-22	Albers Jeffrey W.	Buy	50 000	Stock Option (Right to Buy)

INSIDER POWER
-5.30
Last 85 transactions
Buy: 64 136 392 \| Sell: 71 129 759

Volume Correlation

Long: 0.44 (neutral)

Short: -0.73 (moderate negative)

Signal:(64.735) Neutral

Aeglea Bio Therapeutics Correlation

10 Most Positive Correlations
GAINL	0.987
RETA	0.975
PRVB	0.967
ULBI	0.966
RDUS	0.964
SQL	0.96
HURN	0.948
CSSE	0.946
SONN	0.945
SGMO	0.945

10 Most Negative Correlations
BOCH	-0.967
LMRK	-0.964
SBNYP	-0.962
SHSP	-0.956
TIOA	-0.944
MSDA	-0.941
ANIK	-0.939
MSDAU	-0.938
SKYA	-0.938
QADA	-0.937

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Aeglea Bio Therapeutics Correlation - Currency/Commodity

0.21
( neutral )

0.02
( neutral )

0.23
( neutral )

-0.50
( neutral )

0.57
( weak )

0.28
( neutral )

Aeglea Bio Therapeutics Financials

Annual	2022
Revenue:	$2.33M
Gross Profit:	$2.33M (100.00 %)
EPS:	$-24.86

Q3	2023
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-9.34

Q2	2023
Revenue:	$688 000
Gross Profit:	$688 000 (100.00 %)
EPS:	$-56.79

Q1	2023
Revenue:	$198 000
Gross Profit:	$198 000 (100.00 %)
EPS:	$-4.89

Financial Reports:

No articles found.

Aeglea Bio Therapeutics

Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company's lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. It also develops AGLE-177, a polyethylene glycol modified, which is in Phase I/II clinical trial for the treatment of patient with homocystinuria. In addition, the company's preclinical pipeline includes AGLE-325 for the treatment of cystinuria, as well as other research programs. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015. Aeglea BioTherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas.